Panacea Biotec has established and is
operating high standard cGMP manufacturing facilities for pharmaceutical
formulation & vaccines with accreditation from various international
organizations and regulatory bodies.
Pharmaceutical Formulation Plant
Baddi, Himachal Pradesh, India
Situated amidst picturesque surroundings in the state of Himachal Pradesh,
Panacea Biotecís facility in Baddi is currently catering to manufacturing of
oral pharmaceutical finished dosage forms. The facility is equipped with
modern equipment and machinery to met the regulatory standards of the US,
European & South African markets.
The facility is spread over 70,000 sqm with
dedicated blocks for
Tablets, Hard Gelatin Capsules, Liquid Orals
Soft Gelatin formulation with a dedicated
line for immunosuppressants
Dietary Supplements / Herbal Formulations : Tablets /
Rifampicin based oral finished dosage forms
Vaccine Formulation Plant
New Delhi, India
This is a state of the art manufacturing facility located in the capital of
India, New Delhi. With a built up area of more than more than 50,000 sq ft.
it has three vial filling lines
This is a WHO cGMP approved facility with WHO Pre-qualification for Oral
Polio Vaccines. The facility has been designed, constructed and maintained
to suit production of vaccines following Good Manufacturing Practices.
Provision has also been made for a separate filling line for prefilled
Vaccine Formulation Plant
Lalru, Punjab, India
This facility has been set up to manufacture recombinant Hepatitis B Vaccine along
with other products using recombinant DNA technology for filling, packing and
final processing. This facility is spread over 50 acres and the complex also
houses facilities for Research and Development Laboratories, Animal House
and Effluent Treatment Plant.
The manufacturing facility includes physically segregated Upstream
processing area, Down stream processing area, Formulation area, Cold rooms and Critical systems & utility area. The premises is
designed, constructed, adapted and maintained to suit the production of
recombinant vaccines following current Good Manufacturing Practices (cGMPs).
The layout and design aims to minimize the risk of errors and permit
effective cleaning and maintenance in order to avoid contamination, mix-up,
and unidirectional personnel and material flow. Separate cold rooms are
provided for the storage of in process and the finished products under
quarantine and release.
State-of-the-art manufacturing facilities
for Bacterial Product vaccines.
Facility for Cell Culture based vaccines.
Upcoming Fermentation based Pilot Plant for
scale-up studies of new vaccines and biopharmaceutical
A new Vaccine Formulation and Filling Unit
under construction to meet requirement of final product filling and